NCT06081829View on ClinicalTrials.gov

A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 10, 2023

Primary Completion Date

October 1, 2024

Study Completion Date

May 31, 2027

Conditions
Cholangiocarcinoma Non-resectableCholangiocarcinoma Metastatic
Interventions
DRUG

Ivosidenib

Subjects will take 2 tablets (500 mg total) orally once daily.

Trial Locations (7)

277-8577

National Cancer Center Hospital East (JPN-002), Kashiwa

860-8556

Kumamoto University Hospital (JPN-004), Kumamoto

791-0280

National Hospital Organization Shikoku Cancer Center (JPN-007), Matsuyama

541-8567

Osaka International Cancer Institute (JPN-005), Osaka

060-8648

Hokkaido University Hospital (JPN-006), Sapporo

Unknown

National Cancer Center Hospital (JPN-001), Tokyo

241-8515

Kanagawa Cancer Center (JPN-003), Yokohama

All Listed Sponsors
lead

Servier

INDUSTRY

NCT06081829 - A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation | Biotech Hunter | Biotech Hunter